C4 Therapeutics, Inc. (CCCC) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

High Risk

Significant dilution risk

Last updated: May 12, 2026

Risk Assessment Details

Potential Dilution: 84.64% of current shares

Recent Dilution: 90.43% (2 years)

Historical Dilution Factor: significant recent dilution

Outstanding Shares

110M

Potential Supply

94M

Additional shares possible

Splits

None

Past 2 years

Summary

CCCC currently has 111M outstanding shares. with significant dilution risk as 93.6M authorized shares could dilute existing holders by 84.6%. The company has significantly diluted shareholders by 90.43% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
May 12, 2026	10-Q filing \| 110.6M shares outstanding	110M	94M
Nov 21, 2025	S-3 filing: This S-3 filing outlines an offering of common stock with an aggregate offering price of up to $125,000,000 through an at-the-market offering.	74M	94M
Nov 06, 2025	10-Q filing \| 96.9M shares outstanding	97M	41M
Aug 07, 2025	10-Q filing \| 71.0M shares outstanding	71M	41M
May 07, 2025	10-Q filing \| 70.8M shares outstanding	71M	41M
Feb 27, 2025	10-K filing \| 69.4M shares outstanding	69M	41M
Oct 31, 2024	S-3 filing: The company is offering shares of common stock with an aggregate offering price of up to $200,000,000 through an at-the-market offering.	71M	41M
Oct 31, 2024	S-3 filing: The filing registers the resale of up to 4,874,550 shares of common stock by the selling stockholder.	71M	41M
Oct 31, 2024	10-Q filing \| 69.6M shares outstanding	70M	41M
Aug 01, 2024	10-Q filing \| 68.8M shares outstanding	69M	2.9M
May 08, 2024	10-Q filing \| 68.4M shares outstanding	68M	2.9M
Feb 22, 2024	10-K filing \| 68.6M shares outstanding	69M	2.9M
Nov 01, 2023	10-Q filing \| 49.2M shares outstanding	49M	2.9M
Aug 08, 2023	10-Q filing \| 49.1M shares outstanding	49M	2.9M
May 04, 2023	10-Q filing \| 49.0M shares outstanding	49M	2.9M
Feb 23, 2023	POS AM filing: The company is offering shares of its common stock having an aggregate offering price of up to $200,000,000 through an at-the-market offering.	49M	2.9M
Feb 23, 2023	10-K filing \| 48.9M shares outstanding	49M	2.9M
Nov 03, 2022	10-Q filing \| 48.9M shares outstanding	49M	2.9M
Aug 04, 2022	10-Q filing \| 48.8M shares outstanding	49M	2.9M
May 05, 2022	10-Q filing \| 48.8M shares outstanding	49M	2.9M
Feb 24, 2022	10-K filing \| 48.7M shares outstanding	49M	2.9M
Nov 10, 2021	10-Q filing \| 48.6M shares outstanding	49M	2.9M
Aug 11, 2021	10-Q filing \| 48.5M shares outstanding	48M	2.9M
Jun 14, 2021	S-1 filing: This is an S-1 filing for an initial public offering of common stock.	43M	2.9M
May 13, 2021	10-Q filing \| 43.2M shares outstanding	43M	2.9M
Mar 11, 2021	10-K filing \| 43.1M shares outstanding	43M	2.9M
Nov 12, 2020	10-Q filing \| 43.0M shares outstanding	43M	2.9M
Sep 28, 2020	S-1/A filing: This S-1/A filing relates to a company offering common stock, with a directed share program for insiders and related parties, and includes representations and warranties regarding compliance with securities laws and other regulations.	32M	2.9M
Sep 10, 2020	S-1 filing: This is an S-1 filing for the initial public offering of C4 Therapeutics, Inc. detailing the number of shares outstanding, and equity plans.	270M	2.9M

Back to CCCC Details